Takehisa Kitazawa
Overview
Explore the profile of Takehisa Kitazawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
681
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakagawa K, Yamazaki M, Tanimura H, Sakaguchi N, Kohara M, Sato I, et al.
Sci Rep
. 2025 Feb;
15(1):7102.
PMID: 40016251
Postoperative adhesions frequently occur following abdominal surgical interventions, leading to serious morbidities and requiring new therapeutic strategies. The development of new therapeutic agents to reduce postoperative adhesions needs animal models...
2.
Kamikawa T, Kimura N, Ishii S, Muraoka M, Kodama T, Taniguchi K, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39401967
Background: Ovarian cancer remains a formidable challenge in oncology, necessitating innovative therapeutic approaches. Claudin-6 (CLDN6), a member of the tight junction molecule CLDN family, exhibits negligible expression in healthy tissues...
3.
Nakajima Y, Ogiwara K, Inaba K, Kitazawa T, Nogami K
Haemophilia
. 2024 Oct;
30(6):1435-1439.
PMID: 39368058
No abstract available.
4.
Oda A, Takeyama M, Kitazawa T, Nogami K
Thromb Res
. 2024 Apr;
237:108-111.
PMID: 38579512
No abstract available.
5.
Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, et al.
Cancer Immunol Res
. 2024 Apr;
12(6):719-730.
PMID: 38558120
Small-cell lung cancer (SCLC) is an aggressive cancer for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives for ICI-resistant tumors, but...
6.
Yada K, Fujitate N, Ogiwara K, Soeda T, Kitazawa T, Nogami K
Thromb Res
. 2024 Mar;
237:37-45.
PMID: 38547693
Background: The hemostatic effect of recombinant (r) factor (F)VIIa after repetitive intermittent administration may be attenuated in patients with hemophilia A (PwHA) with inhibitors (PwHAwI) creating a clinically unresponsive status,...
7.
Nakajima Y, Ogiwara K, Inaba K, Kitazawa T, Nogami K
Thromb Res
. 2024 Mar;
237:14-17.
PMID: 38531118
No abstract available.
8.
Fukuda H, Arai K, Mizuno H, Nishito Y, Motoi N, Arai Y, et al.
Cancer Sci
. 2024 Mar;
115(6):1763-1777.
PMID: 38527308
Overcoming resistance to immune checkpoint inhibitors is an important issue in patients with non-small-cell lung cancer (NSCLC). Transcriptome analysis shows that adenocarcinoma can be divided into three molecular subtypes: terminal...
9.
Okura Y, Ikawa-Teranishi Y, Mizoroki A, Takahashi N, Tsushima T, Irie M, et al.
Nat Commun
. 2023 Dec;
14(1):8502.
PMID: 38135691
In human celiac disease (CeD) HLA-DQ2.5 presents gluten peptides to antigen-specific CD4 T cells, thereby instigating immune activation and enteropathy. Targeting HLA-DQ2.5 with neutralizing antibody for treating CeD may be...
10.
Nakajima Y, Ogiwara K, Inaba K, Kitazawa T, Nogami K
Res Pract Thromb Haemost
. 2023 Dec;
8(1):102271.
PMID: 38115953
Background: Activated protein C (APC) inactivates activated factor (F) V (FVa) and FVIIIa. NXT007, an emicizumab-based engineered therapeutic bispecific antibody, enhances the coagulation potential of FVIII-deficient plasma (FVIIIdef-plasma) to near...